Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus

Abstract

Introduction

The objective of this study is to determine whether serum concentrations of B cell activating factor from the tumour necrosis factor family (BAFF) and/or a proliferation-inducing ligand (APRIL) are associated with clinical manifestations of systemic lupus erythematosus (SLE).

Methods

BAFF and APRIL concentrations were quantified using a commercial ELISA in serum samples obtained at the time of clinical assessment in 98 patients, and on 245 samples from 75 of these patients followed prospectively.

Results

Serum BAFF was significantly increased, and APRIL decreased, in patients with either renal or central nervous system (CNS) lupus. In contrast, in cross-sectional analysis, there was no correlation between disease activity (SLEDAI-2k) and serum BAFF or APRIL. In longitudinal follow-up, there was no association between changes in serum BAFF or APRIL and changes in SLEDAI-2k, or between baseline serum BAFF or APRIL and subsequent changes in SLEDAI-2k. However, between-visit changes in BAFF were significantly different in patients with increases in SLEDAI-2k ≥ 4, compared to patients whose SLEDAI-2k did not change.

Conclusions

Although neither serum BAFF nor APRIL correlated with disease activity in the overall population, elevated serum BAFF and reduced APRIL may be markers of renal and CNS disease in SLE patients.

Keywords

A proliferation-inducing ligand (APRIL)autoimmunity B cell activating factor from the tumour necrosis factor family (BAFF)innate immunity renal lupus systemic lupus erythematosus (SLE)

Get full access to this article

View all access options for this article.

References

Tsokos

. Systemic lupus erythematosus. N Engl J Med 2011; 365: 2110–2121.

Illei

Tackey

Lapteva

Lipsky

. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum 2004; 50: 2048–2065.

Bertsias

Salmon

Boumpas

. Therapeutic opportunities in systemic lupus erythematosus: State of the art and prospects for the new decade. Ann Rheum Dis 2010; 69: 1603–1611.

Baechler

Batliwalla

Karypis

. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610–2615.

Kirou

Lee

George

Louca

Peterson

MGE

Crow

. Activation of the interferon‐α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52: 1491–1503.

Feng

Grossman

. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2951–2962.

Landolt-Marticorena

Bonventi

Lubovich

. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2009; 68: 1440–1446.

Vuyyuru

Mohan

Manser

Rahman

. The lupus susceptibility locus Sle1 breaches peripheral B cell tolerance at the antibody-forming cell and germinal center checkpoints. J Immunol 2009; 183: 5716–5727.

Liu

. Sle3 and Sle5 can independently couple with Sle1 to mediate severe lupus nephritis. Genes Immun 2007; 8: 634–645.

10.

Mills

. Systemic lupus erythematosus. N Engl J Med 1994; 330: 1871–1879.

11.

Kotzin

. Systemic lupus erythematosus. Cell 1996; 85: 303–306.

12.

Vincent FB, Saulep-Easton D, Figgett WA, et al. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 2013; 24: 29–40.

13.

Belnoue

Pihlgren

McGaha

. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008; 111: 2755–2764.

14.

Mackay

Woodcock

Lawton

. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697–1710.

15.

Gross

Johnston

Mudri

. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995–999.

16.

Navarra

Guzmán

Gallacher

. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721–731.

17.

Furie

Petri

Zamani

. A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits BLyS, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918–3930.

18.

Dall'Era

Chakravarty

Wallace

. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56: 4142–4150.

19.

Koyama

Tsukamoto

Miyagi

. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 1065–1067.

20.

Zhang

Roschke

Baker

. Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6–10.

21.

Dillon

Harder

Lewis

. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther 2010; 12: R48–R48.

22.

Morel

Roubille

Planelles

. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus. Ann Rheum Dis 2009; 68: 997–1002.

23.

Hegazy

Darwish

Darweesh

El-Shehaby

Emad

. Raised serum level of APRIL in patients with systemic lupus erythematosus: Correlations with disease activity indices. Clin Immunol 2010; 135: 118–124.

24.

Stohl

Metyas

Tan

. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004; 63: 1096–1103.

25.

Cheema

Roschke

Hilbert

Stohl

. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313–1319.

26.

Petri

Stohl

Chatham

. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 2453–2459.

27.

Petri

Stohl

Chatham

. Association of BLyS™ with measures of disease activity in a prospective SLE observational study. Arthritis Rheum 2004; 50: S603–S603.

28.

Stohl

Hiepe

Latinis

. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2328–2337.

29.

Tan

Cohen

Fries

. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

30.

Petri

Kim

Kalunian

. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550–2558.

31.

Stoll

Seifert

Isenberg

. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996; 35: 248–254.

32.

Ibañez

Urowitz

Gladman

. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol 2003; 30: 1977–1982.

33.

Ibañez

Gladman

Urowitz

. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005; 32: 824–827.

34.

Rönnblom

. Potential role of IFNalpha in adult lupus. Arthritis Res Ther 2010; 12(Suppl 1): S3–S3.

35.

George-Chandy

Trysberg

Eriksson

. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: Relationship to neuropsychiatric symptoms. Arthritis Res Ther 2008; 10: R97–R97.

36.

Dooley

Houssiau

Aranow

. Effect of belimumab treatment on renal outcomes: Results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013; 22: 63–72.

37.

Roschke

Sosnovtseva

Ward

. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002; 169: 4314–4321.

38.

Vallerskog

Heimbürger

Gunnarsson

. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006; 8: R167–R167.

39.

Jonsson

Szodoray

Jellestad

Jonsson

Skarstein

. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol 2005; 25: 189–201.

40.

Stohl

Metyas

Tan

. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis Rheum 2003; 48: 3475–3486.

41.

Collins

Gavin

Migone

Hilbert

Nemazee

Stohl

. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: Disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006; 8: R6–R6.

42.

Thumboo

Uramoto

O’Fallon

. A comparative study of the clinical manifestations of systemic lupus erythematosus in Caucasians in Rochester, Minnesota, and Chinese in Singapore, from 1980 to 1992. Arthritis Rheum 2001; 45: 494–500.

43.

Bossen

Cachero

Tardivel

. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008; 111: 1004–1012.